Sihuan Pharmaceutical Holdings Group Ltd. · HKEX:460
Sihuan Pharmaceutical — FY2024 Earnings Presentation
32 slides from Sihuan Pharmaceutical's earnings presentation, March 2025
Slide 1: 2024 Annual Results Presentation
Sihuan Pharmaceutical Holdings Group Ltd. 四环医药控股集团有限公司 (incorporated in Bermuda with limited liability) （于百慕达注册成立之有限公司) Stock Code 股份代号：0460 2024 Annual Results Presentation March 2025 Building China’s Leading Medical Aesthetic and Biopharmaceutical Company with Rigor and Innovation of a Pharmaceuti
Slide 2: Disclaimer
Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase sec
Slide 3: Category
Promoting Sihuan Pharm’s 2.0 Version in Full Speed Industrial upgrade and develop to leading medical aesthetic and innovative pharmaceutical company Category 01 Company Overview 02 Business Highlights of FY24 03 Focusing on High-Growth Medical Aesthetic Business 04 Annual Results Review 05 Appendix
Slide 4: Building China's Leading Medical Aesthetic and Biopharmaceutical Company
Building China’s Leading Medical Aesthetic and Biopharmaceutical Company with Rigor and Innovation of a Pharmaceutical Company Insist in the dual wheel drive of “medical aesthetic+innovative pharmaceutical”, successfully transform and upgrade to innovation Medical Revenue 744.2 million Generic High-
Slide 5: Investment Highlight of Sihuan Pharm
Investment Highlight of Sihuan Pharm High-growth medical aesthetic business Innovation-driven product pipeline Mature commercialization platform Building China’s leading medical aesthetic Adhering to the upgrading and transformation to High efficiency, low cost, full dosage form platform with full p
Slide 6: Business Highlights of FY24
Business Highlights of FY24 Successfully realizing the transformation and upgrading to medical aesthetics and innovative pharmaceuticals 6
Slide 7: FY24 Highlights
FY24 Highlights Realized a number of business breakthroughs under the core of “innovation-driven + resource integration” Successfully realizing the 28 new products were approved for marketing, 4 into key milestones in clinical trials strategic transformation Medical Aesthetic Diabetes and complicati
Slide 8: 60+ Medical Aesthetic Products and 40+ Innovative Drugs/Biologics
60+ Medical Aesthetic Products and 40+ Innovative Drugs/Biologics The pipeline includes multiple blockbuster medical aesthetic products & rich / high-value biopharmaceutical products Category Therapy Area Product Name Company Business Pre-clinical Clinical Registration Launch Shaping Botulinum toxin
Slide 9: Rapid Progress in Product R&D and Registration
Rapid Progress in Product R&D and Registration 28 new products approved for marketing，4 into key milestones in clinical trials，bringing new momentum to future revenue growth Medical aesthetic products approved in FY24 7 Medicine approved in FY24 21 • Dual-wave RF Sylfirm X • Innovative drug: Ganagli
Slide 10: Deepening the Layout of Sales Channel
Deepening the Layout of Sales Channel, with Remarkable Results in Market Penetration in Medical Aesthetic and Innovative Drug Industries Medical aesthetic sales focus on refined operation, while innovative drug and biologics sales advanced rapidly Innovative Medical Refined operation, optimized drug
Slide 11: BD Strengthens the Layout in Core Areas, Accelerates Commercialization of New Products
BD Strengthens the Layout in Core Areas， Accelerates Commercialization of New Products Continuously targeting business expansion in the light medical aesthetic field and promoting the rapid commercialization of pharmaceutical products in multiple ways. Product NRDL Out-licensing Introduction & VBP M
Slide 12: ESG Awards in FY24
Awards in FY24 ESG Awards The 3rd International Green Zero 14th China Philanthropy Carbon Festival Gelonghui Jinge Awards Festival and ESG Summit Outstanding 2024 ESG Exemplary 2024 ESG Enterprise in Enterprise Innovation Award ESG Innovation Award and Practice China Listed Company Industry Healthca
Slide 13: Development Goals and Strategies
Development Goals and Strategies The Group has formed a synergistic industrial pattern with a rich pipeline of light medical aesthetics and innovative pharmaceutical products and a mature commercialization network, successfully realizing a substantial transformation into an innovation-driven enterpr
Slide 14: Focus on medical aesthetic business with high growth
Focus on medical aesthetic business with high growth Revenue of medical aesthetic business grow 65.4% yoy 14
Slide 15: Precise Focus on Medical Aesthetic Business, Achieving High Revenue Growth in FY24
Precise Focus on Medical Aesthetic Business, Achieving High Revenue Growth in FY24 Meiyan Space: Leading the high quality development of medical aesthetic business with the rigorous genes of a pharmaceutical company 744.2 251.0 Segment million Segment million Revenue increase 65.4% yoy Results incre
Slide 16: 7 Products Approved in FY24, New Regenerative Products Added to the Pipeline
7 Products Approved in FY24，New Regenerative Products were added to the pipeline A rich product pipeline that covers the needs of beauty lovers throughout their life cycle Business Category Product Pre-clinical Clinical Registration Marketing PLLA gel Class II Products approved in FY24 self-develope
Slide 17: Strengthen the Direct Sale + Distributor Dual-channel Model
Continuously Strengthen the “Direct Sale + Distributor” Dual-channel Model in FY24, Driving the Medical Aesthetic Matrix to Take the Lead Comprehensively optimize marketing strategies, strengthen strategic cooperation, enhance in-depth empowerment, and successfully promote the business upgrading and
Slide 18: Establish Medical Aesthetic Energy-based Device Division
Establish Medical Aesthetic Energy-based Device Division, Focus On Expanding the Optoelectronic Device Business The efficacy, safety, and comfort of Sylfirm X have been highly recognized by KOLs, clinicians, and beauty seekers, and the brand's influence continues to expand World’s first FDA and NMPA
Slide 19: Multi-dimensional and Multi-session Marketing Activities
Multi-dimensional and Multi-session Marketing Activities, In-depth Empowerment of Medical Aesthetic Institutions Customers Comprehensively promote brand influence, organization cooperation efficiency and consumption conversion, injecting strong momentum for business growth Regional conference Le you
Slide 20: Creating an Academic Highland for Medical Aesthetics
Creating an Academic Highland for Medical Aesthetics and Building a Barrier for Differentiated Competition ✓ Tanmei Space training base establishment Collaboration with top industrial academic ✓ 1st batch of CAPA Medical Aesthetic Adverse Reaction conferences ✓ Treatment Center Continuing education
Slide 21: Accelerate Internationalization of Medical Aesthetics Through U.S. Subsidiary Genesis
Accelerate Internationalization of Medical Aesthetics Through the U.S. Subsidiary Genesis Fully acquired Genesis Biosystems in 2021, providing strong support for Sihuan Pharmaceutical's internationalization of medical aesthetics Internationalization layout International market Fully acquired Genesis
Slide 22: Brand Enterprise Outstanding Partners
Win High Market Recognition with Awards on Branding and From Partner MCC2024 China Medical Aesthetic Equipment Annual Selection Brand Enterprise Lancy Medical Aesthetic Outstanding Partners 22
Slide 23: Annual Financial Review
DOT 24 SithuanPharm Annual Financial Review 23
Slide 24: Revenue of the Group: RMB 1.9 Billion
Revenue of the Group：RMB 1.9 Billion, with Revenue and Profit of the Medical Aesthetic Segment Growing at High Rate The traditional generic medicine business has been severely affected by government industry policies, resulting in a decline in revenue and profits of the generic medicine business. RM
Slide 25: Medical Aesthetic Business Achieved High Revenue Growth
The Medical Aesthetic Business Achieved High Revenue Growth：Approximately RMB 0.74 Billion, Representing an Increase of Approximately 65.4% YOY The products have been highly recognised by the market, driving a significant growth in the revenue of the medical aesthetic business, and the sales of new
Slide 26: Revenue Growth in the Innovative and Other Medicine Segment
Revenue Growth in the Innovative and Other Medicine Segment：Approximately RMB 57.6 Million, Representing an Increase of Approximately 388.1% YOY Anaprazole Sodium, a first-class new drug developed by Xuanzhu Biopharm, was approved for launching to the market in the second half of 2023 and began to g
Slide 27: Revenue of the Generic Medicine Segment Decreased
Revenue of the Generic Medicine Segment Decreased：Approximately RMB 1.1 Billion, Representing a Decrease of Approximately 21.4% YOY Some of the generic medicine has been severely affected by government industry policies, resulting in a decline in selling price and sales volume Segment Revenue Profit
Slide 28: R&D Expenses Progressively Decline
R&D Expenses Progressively Decline：Approximately RMB 0.47 million, Representing 41.0% of Revenue from Medicine Sales Continued large-scale R&D investment has driven the Group to rapidly achieve transformation and development from generic medicine to innovative medicine Research and Development Expen
Slide 29: Appendix
OAR SihuanPharm Appendix 29
Slide 30: Milestones
Milestones • Hainan Sihuan Pharmaceutical Co., Ltd. Founded • In Forbes China 2010, ranked first among • Letybo approved for launch in China, it is the • Non-PVC solid-liquid dual chamber bags 2024 Chinese pharmaceutical companies fourth botulinum toxin product approved in China and Midazolam Oromuc
Slide 31: A total of 28 products were approved for launch in 2024
A total of 28 products were approved for launch in 2024, bringing new momentum to future revenue growth Rich pipeline of biologics, rapid progress in R&D and registration *The following data statistics to 31 December, 2024 Preclinical Clinical (include IND) NDA/ANDA Approval/Commercialization 2 6 2
Slide 32: Thank you!
Thank you！ IR Department ir.sihuanpharm.com E: ir@sihuanpharm.com 32
Sihuan Pharmaceutical Holdings Group — FY2024 Earnings Presentation on 6ix